| Biomarker ID | 938 |
| PMID | 22674214 |
| Year | 2012 |
| Biomarker | PCA3 + TMPRSS2:ERG gene fusion |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Normal adjacent to Prostate (NP) Vs Low Grade PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 48 Benign Prostatic Hyperplasia (BPH), 32 Normal adjacent to Prostate (NP), and 48 PCa samples (20 Low grade, 28 High Grade) were taken in the study. |
| Senstivity | 9362% |
| Specificity | 9750% |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | quantitative real time polymerase chain reactions (qRT-PCR) |
| Clinical | No |
| Remarks | LG: GS>7, HG: 7 and above |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PCA3, ERG |